<DOC>
	<DOCNO>NCT01213810</DOCNO>
	<brief_summary>The goal demonstrate immunogenicity safety Zostavax® HIV positive individual . Study participant stratify different patient group accord CD4 cell count , viral load HIV Status . - Trial medicinal product - Trial immunomodulatory product / biological</brief_summary>
	<brief_title>Prevention Varicella Zoster Virus ( VZV ) -Reactivation HIV-positive Individuals Enrolled Prospective Immunogenicity Safety Trial VZV Vaccine : PROVE-IT-Study</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : All individual Age &gt; 18 year Male , female negative urine pregnancy test VZVseropositive ( serologically document ) Agree use barrier method birth control ( condom ) Written informed consent HIV positive individual ART ( group A1A3 ) Continuous ART &gt; 3 month baseline No change ART regimen within 1 month baseline HIVRNA ( value must &lt; 3 month old ) &lt; 50 copies/ml last visit CD4count ( value must &lt; 3 month old ) &gt; 500 cells/µl group A1 , 350500 cells/µl group A2 250 349 cells/µl group A3 Participation SHCS HIVpositive individual without ART ( group B ) HIV1 RNA &gt; 1000 copies/ml ( &lt; 3 month baseline ) CD4cell count &gt; 500 cells/µl ( &lt; 3 month baseline ) Participation SHCS Healthy HIVnegative volunteer ( group C ) Negative HIVscreening test ( &lt; 3 month baseline ) CD4 cell count &gt; 500 cells/µl Exclusion criterion : Common exclusion criterion Contraindications ethical ground Involvement conflicting ( vaccine investigational drug ) clinical trial ( except participation Swiss HIV Cohort Study ) . Inability follow procedure study , e.g . due language problem , psychological disorder dementia subject . Pregnancy breast feeding . Other clinically relevant concomitant disease state ( e.g. , renal failure , hepatic dysfunction , cardiovascular disease , etc ) , Known suspect noncompliance , drug alcohol abuse . Specific exclusion criterion Fever &gt; 38.3 °C acute illness last 4 week Exposure chickenpox shingle within four week prior study entry History shingle Immunosuppression due disease ( HIV ) due medication within 30 day study entry ( eg corticosteroid ) Household contact know immunodeficiency ( e.g . HIVpositive CD4 &lt; 250 cells/µl ) Immunoglobulin blood product treatment within 1 year prior 2 month study vaccination Previous allergic reaction vaccine component ( i.e . neomycin gelatin ) Vaccination life attenuate vaccine one month prior study entry History chickenpox vaccination Treatment antiherpes drug 4 week baseline Severe coagulation disorder oral anticoagulant treatment Laboratory exclusion criterion . Thrombocytopenia &lt; 50x 103/ ? l Haemoglobin &lt; 12 g/dl More threefold elevation ALT Creatinine than150 µmol/l Glucose &gt; 10 mmol/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>VZV ( Varicella zoster Virus )</keyword>
	<keyword>vaccine</keyword>
	<keyword>T cell</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
</DOC>